272 related articles for article (PubMed ID: 22748659)
1. IDH mutations in human glioma.
Kim W; Liau LM
Neurosurg Clin N Am; 2012 Jul; 23(3):471-80. PubMed ID: 22748659
[TBL] [Abstract][Full Text] [Related]
2. Glioma-derived mutations in IDH: from mechanism to potential therapy.
Fu Y; Huang R; Du J; Yang R; An N; Liang A
Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884
[TBL] [Abstract][Full Text] [Related]
3. Isocitrate dehydrogenase 1: what it means to the neurosurgeon: a review.
Hodges TR; Choi BD; Bigner DD; Yan H; Sampson JH
J Neurosurg; 2013 Jun; 118(6):1176-80. PubMed ID: 23581583
[TBL] [Abstract][Full Text] [Related]
4. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
[TBL] [Abstract][Full Text] [Related]
5. Isocitrate dehydrogenase mutations: a challenge to traditional views on the genesis and malignant progression of gliomas.
Weller M; Wick W; von Deimling A
Glia; 2011 Aug; 59(8):1200-4. PubMed ID: 21294161
[TBL] [Abstract][Full Text] [Related]
6. IDH1 and IDH2 mutations in gliomas.
Cohen AL; Holmen SL; Colman H
Curr Neurol Neurosci Rep; 2013 May; 13(5):345. PubMed ID: 23532369
[TBL] [Abstract][Full Text] [Related]
7. Isocitrate dehydrogenase mutation as a therapeutic target in gliomas.
Han CH; Batchelor TT
Chin Clin Oncol; 2017 Jun; 6(3):33. PubMed ID: 28705010
[TBL] [Abstract][Full Text] [Related]
8. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas.
Olar A; Wani KM; Alfaro-Munoz KD; Heathcock LE; van Thuijl HF; Gilbert MR; Armstrong TS; Sulman EP; Cahill DP; Vera-Bolanos E; Yuan Y; Reijneveld JC; Ylstra B; Wesseling P; Aldape KD
Acta Neuropathol; 2015 Apr; 129(4):585-96. PubMed ID: 25701198
[TBL] [Abstract][Full Text] [Related]
9. Yet another utility for isocitrate dehydrogenase.1: Can it serve as an immunomarker to assess tumor margins in gliomas?
Rao S; Rajkumar A; Sundaram S; Joyce ME; Duvuru P
J Cancer Res Ther; 2020; 16(6):1476-1481. PubMed ID: 33342816
[TBL] [Abstract][Full Text] [Related]
10. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase 1 and 2 mutations in gliomas.
Megova M; Drabek J; Koudelakova V; Trojanec R; Kalita O; Hajduch M
J Neurosci Res; 2014 Dec; 92(12):1611-20. PubMed ID: 25078896
[TBL] [Abstract][Full Text] [Related]
12. Isocitrate dehydrogenase mutations in gliomas: mechanisms, biomarkers and therapeutic target.
Guo C; Pirozzi CJ; Lopez GY; Yan H
Curr Opin Neurol; 2011 Dec; 24(6):648-52. PubMed ID: 22002076
[TBL] [Abstract][Full Text] [Related]
13. [Mutations of IDH1 and 2 genes: a molecular diagnosis of low-grade gliomas].
Larsen CJ
Bull Cancer; 2009 Jun; 96(6):641-2. PubMed ID: 19585679
[No Abstract] [Full Text] [Related]
14. Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas.
Cai J; Zhu P; Zhang C; Li Q; Wang Z; Li G; Wang G; Yang P; Li J; Han B; Jiang C; Sun Y; Jiang T
Oncotarget; 2016 Mar; 7(13):16384-95. PubMed ID: 26918938
[TBL] [Abstract][Full Text] [Related]
15. From genomics to the clinic: biological and translational insights of mutant IDH1/2 in glioma.
Dunn GP; Andronesi OC; Cahill DP
Neurosurg Focus; 2013 Feb; 34(2):E2. PubMed ID: 23373447
[TBL] [Abstract][Full Text] [Related]
16. Molecular features assisting in diagnosis, surgery, and treatment decision making in low-grade gliomas.
Chen R; Ravindra VM; Cohen AL; Jensen RL; Salzman KL; Prescot AP; Colman H
Neurosurg Focus; 2015 Mar; 38(3):E2. PubMed ID: 25727224
[TBL] [Abstract][Full Text] [Related]
17. Expanding the spectrum of IDH1 mutations in gliomas.
Gupta R; Flanagan S; Li CC; Lee M; Shivalingham B; Maleki S; Wheeler HR; Buckland ME
Mod Pathol; 2013 May; 26(5):619-25. PubMed ID: 23307057
[TBL] [Abstract][Full Text] [Related]
18. An analysis of 170 glioma patients and systematic review to investigate the association between IDH-1 mutations and preoperative glioma-related epilepsy.
Yang Y; Mao Q; Wang X; Liu Y; Mao Y; Zhou Q; Luo J
J Clin Neurosci; 2016 Sep; 31():56-62. PubMed ID: 27406953
[TBL] [Abstract][Full Text] [Related]
19. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
[TBL] [Abstract][Full Text] [Related]
20. Segregation of non-p.R132H mutations in IDH1 in distinct molecular subtypes of glioma.
Gravendeel LA; Kloosterhof NK; Bralten LB; van Marion R; Dubbink HJ; Dinjens W; Bleeker FE; Hoogenraad CC; Michiels E; Kros JM; van den Bent M; Smitt PA; French PJ
Hum Mutat; 2010 Mar; 31(3):E1186-99. PubMed ID: 20077503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]